Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 5 (2008), Issue 1 (January)

1. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
   J Thorac Oncol, 3(1): 68-74. [Abstract] [Full-text]
2. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
   J Thorac Oncol, 3(1): 59-67. [Abstract] [Full-text]
3. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
   J Thorac Oncol, 3(1): 37-45. [Abstract] [Full-text]
4. Randomized multicenter trial of more intense and standard early verteporfin treatment of neovascular age-related macular degeneration.
   Ophthalmology, 115(1): 134-40. [Abstract] [Full-text]
5. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.
   Ophthalmology, 115(1): 141-6. [Abstract] [Full-text]
6. Systematic evaluation of errors occurring during the preparation of intravenous medication.
   CMAJ, 178(1): 42-8. [Abstract] [Full-text]
7. Oxystress inducing antitumor therapeutics via tumor-targeted delivery of PEG-conjugated D-amino acid oxidase.
   Int J Cancer, 122(5): 1135-44. [Abstract] [Full-text]
8. Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments.
   Int J Cancer, 122(5): 1155-63. [Abstract] [Full-text]
9. Interactions between intakes of alcohol and postmenopausal hormones on risk of breast cancer.
   Int J Cancer, 122(5): 1109-13. [Abstract] [Full-text]
10. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    J Natl Cancer Inst, 100(1): 14-20. [Abstract] [Full-text]
11. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
    J Natl Cancer Inst, 100(1): 32-40. [Abstract] [Full-text]
12. Development of amphiphilic gamma-PGA-nanoparticle based tumor vaccine: potential of the nanoparticulate cytosolic protein delivery carrier.
    Biochem Biophys Res Commun, 366(2): 408-13. [Abstract] [Full-text]
13. The construction and in vitro testing of photo-activatable cancer targeting folated anti-CD3 conjugates.
    Biochem Biophys Res Commun, 366(2): 526-31. [Abstract] [Full-text]
14. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    N Engl J Med, 358(1): 36-46. [Abstract] [Full-text]
15. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.
    Lancet, 371(9606): 29-40. [Abstract] [Full-text]
16. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
    Lancet Oncol, 9(1): 39-44. [Abstract] [Full-text]
17. Accuracy of oral liquid measuring devices: comparison of dosing cup and oral dosing syringe.
    Ann Pharmacother, 42(1): 46-52. [Abstract] [Full-text]
18. Risk factors for self-reported adverse drug events among Medicare enrollees.
    Ann Pharmacother, 42(1): 53-61. [Abstract] [Full-text]
19. Comparison of left ventricular ejection fraction and inducible ventricular tachycardia in ST-elevation myocardial infarction treated by primary angioplasty versus thrombolysis.
    Am J Cardiol, 101(2): 153-7. [Abstract] [Full-text]
20. Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000).
    Cancer Invest, 26(1): 81-95. [Abstract] [Full-text]
21. Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.
    Cancer Invest, 26(1): 53-9. [Abstract] [Full-text]
22. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
    Cancer Invest, 26(1): 47-52. [Abstract] [Full-text]
23. Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus.
    Biochem Biophys Res Commun, 366(3): 769-74. [Abstract] [Full-text]
24. Studies on a novel doughnut-shaped minitablet for intraocular drug delivery.
    AAPS PharmSciTech, 8(4): E118. [Abstract] [Full-text]
25. Influence of selected formulation variables on the preparation of enzyme-entrapped Eudragit S100 microspheres.
    AAPS PharmSciTech, 8(4): E116. [Abstract] [Full-text]
26. Improved dissolution of oleanolic acid with ternary solid dispersions.
    AAPS PharmSciTech, 8(4): E113. [Abstract] [Full-text]
27. A case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO).
    Cancer Chemother Pharmacol, 61(4): 717-20. [Abstract] [Full-text]
28. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
    Cancer Chemother Pharmacol, 61(4): 689-94. [Abstract] [Full-text]
29. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
    Cancer Chemother Pharmacol, 61(4): 653-9. [Abstract] [Full-text]
30. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.
    Cancer Chemother Pharmacol, 61(4): 623-9. [Abstract] [Full-text]
31. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.
    Cancer Chemother Pharmacol, 61(4): 579-85. [Abstract] [Full-text]
32. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.
    Cancer Chemother Pharmacol, 61(4): 569-77. [Abstract] [Full-text]
33. Intensive insulin therapy and pentastarch resuscitation in severe sepsis.
    N Engl J Med, 358(2): 125-39. [Abstract] [Full-text]
34. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
    BJU Int, 101(3): 308-12. [Abstract] [Full-text]
35. Synthesis of water-soluble dendrimers based on melamine bearing 16 paclitaxel groups.
    Org Lett, 10(2): 201-4. [Abstract] [Full-text]
36. Early use of vasopressors after injury: caution before constriction.
    J Trauma, 64(1): 9-14. [Abstract] [Full-text]
37. The effects of raloxifene and tibolone on homocysteine and vascular histopathological changes.
    Clin Exp Med, 7(4): 149-53. [Abstract] [Full-text]
38. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma.
    Fertil Steril, 89(1): 166-73. [Abstract] [Full-text]
39. Antibiotic prophylaxis for the prevention of recurrent urinary tract infection in children with low grade vesicoureteral reflux: results from a prospective randomized study.
    J Urol, 179(2): 674-9; discussion 679. [Abstract] [Full-text]
40. The efficacy of dihydrotestosterone transdermal gel before primary hypospadias surgery: a prospective, controlled, randomized study.
    J Urol, 179(2): 684-8. [Abstract] [Full-text]
41. Spectroscopic and chromatographic characterization of triflusal delivery systems prepared by using supercritical impregnation technologies.
    J Pharm Biomed Anal, 46(3): 456-62. [Abstract] [Full-text]
42. Pulsed electrical stimulation for control of vasculature: temporary vasoconstriction and permanent thrombosis.
    Bioelectromagnetics, 29(2): 100-7. [Abstract] [Full-text]
43. Illicit drug use and HIV treatment outcomes in a US cohort.
    AIDS, 22(3): 357-65. [Abstract] [Full-text]
44. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
    AIDS, 22(3): 349-56. [Abstract] [Full-text]
45. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy.
    Circulation, 117(2): 192-9. [Abstract] [Full-text]
46. Genome scale enzyme-metabolite and drug-target interaction predictions using the signature molecular descriptor.
    Bioinformatics, 24(2): 225-33. [Abstract] [Full-text]
47. World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group.
    Pediatr Blood Cancer, 50(3): 692-4. [Abstract] [Full-text]
48. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
    Pediatr Blood Cancer, 50(3): 549-53. [Abstract] [Full-text]
49. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL.
    Pediatr Blood Cancer, 50(3): 528-32. [Abstract] [Full-text]
50. Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia.
    Pediatr Blood Cancer, 50(3): 537-41. [Abstract] [Full-text]
51. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma.
    Pediatr Blood Cancer, 50(3): 567-72. [Abstract] [Full-text]
52. Triple intrathecal therapy without cranial irradiation for central nervous system preventive therapy in childhood acute lymphoblastic leukemia.
    Pediatr Blood Cancer, 50(3): 523-7. [Abstract] [Full-text]
53. Treatment of pediatric non-Hodgkin lymphoma in Hungary: 15 years experience with NHL-BFM 90 and 95 protocols.
    Pediatr Blood Cancer, 50(3): 633-5. [Abstract] [Full-text]
54. Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
    Pediatr Blood Cancer, 50(3): 667-70. [Abstract] [Full-text]
55. Fatal adenovirus hepatitis during maintenance therapy for childhood acute lymphoblastic leukemia.
    Pediatr Blood Cancer, 50(3): 647-9. [Abstract] [Full-text]
56. Brainstem primitive neuroectodermal tumors (bstPNET): results of treatment with intensive induction chemotherapy followed by consolidative chemotherapy with autologous hematopoietic cell rescue.
    Pediatr Blood Cancer, 50(3): 715-7. [Abstract] [Full-text]
57. Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
    Pediatr Blood Cancer, 50(3): 636-9. [Abstract] [Full-text]
58. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    J Natl Cancer Inst, 100(2): 121-33. [Abstract] [Full-text]
59. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery.
    Cancer Gene Ther, 15(2): 126-32. [Abstract] [Full-text]
60. Oral lesions as predictors of highly active antiretroviral therapy failure in Brazilian HIV-infected children.
    J Oral Pathol Med, 37(2): 99-106. [Abstract] [Full-text]
61. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.
    Cancer Res, 68(2): 597-604. [Abstract] [Full-text]
62. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy.
    Cancer Res, 68(2): 516-20. [Abstract] [Full-text]
63. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Eur J Haematol, 80(2): 115-26. [Abstract] [Full-text]
64. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Eur J Haematol, 80(2): 133-42. [Abstract] [Full-text]
65. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.
    Eur J Haematol, 80(2): 127-32. [Abstract] [Full-text]
66. Difference in signalling between various hormone therapies in endometrium, myometrium and upper part of the vagina.
    Hum Reprod, 23(2): 298-305. [Abstract] [Full-text]
67. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era.
    J Clin Oncol, 26(3): 474-9. [Abstract] [Full-text]
68. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    J Clin Oncol, 26(3): 468-73. [Abstract] [Full-text]
69. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.
    J Clin Oncol, 26(3): 463-7. [Abstract] [Full-text]
70. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    J Clin Oncol, 26(3): 421-7. [Abstract] [Full-text]
71. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.
    J Clin Oncol, 26(3): 414-20. [Abstract] [Full-text]
72. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.
    J Clin Oncol, 26(3): 440-6. [Abstract] [Full-text]
73. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    J Clin Oncol, 26(3): 447-54. [Abstract] [Full-text]
74. Risk factors in preventable adverse drug events in pediatric outpatients.
    J Pediatr, 152(2): 225-31. [Abstract] [Full-text]
75. Electronic prescribing reduced prescribing errors in a pediatric renal outpatient clinic.
    J Pediatr, 152(2): 214-8. [Abstract] [Full-text]
76. Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
    Br J Surg, 95(2): 191-4. [Abstract] [Full-text]
77. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Clin Infect Dis, 46(4): 507-15. [Abstract] [Full-text]
78. Hormone replacement therapy after treatment of endometrial cancer.
    Gynecol Obstet Invest, 65(1): 35-8. [Abstract] [Full-text]
79. Electrochemotherapy in treatment of tumours.
    Eur J Surg Oncol, 34(2): 232-40. [Abstract] [Full-text]
80. Using saline solutions for ACE washouts.
    Arch Dis Child, 93(2): 149-50. [Abstract] [Full-text]
81. MR defecography: prospective comparison of two rectal enema compositions.
    AJR Am J Roentgenol, 190(2): W118-24. [Abstract] [Full-text]
82. Delta down compared with delta pulse pressure as an indicator of volaemia during intracranial surgery.
    Br J Anaesth, 100(2): 245-50. [Abstract] [Full-text]
83. Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery.
    Oncology, 72(3): 261-4. [Abstract] [Full-text]
84. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas.
    Oncology, 72(3): 255-60. [Abstract] [Full-text]
85. Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
    Oncology, 72(3): 219-25. [Abstract] [Full-text]
86. Time since menopause influences the acute and chronic effect of estrogens on endothelial function.
    Arterioscler Thromb Vasc Biol, 28(2): 348-52. [Abstract] [Full-text]
87. Revoking the privilege: targeting HER2 in the central nervous system.
    Mol Pharmacol, 73(2): 271-3. [Abstract] [Full-text]
88. Characteristics of recipients of free prescription drug samples: a nationally representative analysis.
    Am J Public Health, 98(2): 284-9. [Abstract] [Full-text]
89. Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy.
    Biochem Biophys Res Commun, 367(2): 330-5. [Abstract] [Full-text]
90. Transient left ventricular apical ballooning syndrome after inadvertent epidural administration of potassium chloride.
    Int J Cardiol, 124(1): e14-5. [Abstract] [Full-text]
91. Oral healthcare for HIV-infected patients: an international perspective.
    Expert Opin Pharmacother, 9(3): 387-404. [Abstract] [Full-text]
92. Unintentional intracerebroventricular administration of etomidate and rocuronium.
    Anesth Analg, 106(2): 520-2, table of contents. [Abstract] [Full-text]
93. Experimental selective choriocapillaris photothrombosis using a modified indocyanine green formulation.
    Br J Ophthalmol, 92(2): 276-80. [Abstract] [Full-text]
94. Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption.
    Br J Ophthalmol, 92(2): 231-5. [Abstract] [Full-text]
95. Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign.
    Stroke, 39(2): 379-83. [Abstract] [Full-text]
96. Male varicocele: transcatheter foam sclerotherapy with sodium tetradecyl sulfate--outcome in 244 patients.
    Radiology, 246(2): 612-8. [Abstract] [Full-text]
97. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.
    Radiology, 246(2): 497-507. [Abstract] [Full-text]
98. Mesorectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction.
    Radiology, 246(2): 454-62. [Abstract] [Full-text]
99. Quantifying the impact of a short-interval interruption of insulin-pump infusion sets on glycemic excursions.
    Diabetes Care, 31(2): 238-9. [Abstract] [Full-text]
100. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
     Diabetes Care, 31(2): 210-5. [Abstract] [Full-text]
101. Myocardial performance index during rapidly changing loading conditions: impact of different tidal ventilation.
     Eur J Anaesthesiol, 25(3): 217-23. [Abstract] [Full-text]
102. Acute phase response induction by cancer treatment with photodynamic therapy.
     Int J Cancer, 122(6): 1411-7. [Abstract] [Full-text]
103. New developments in medulloblastoma treatment: the potential of a cyclopamine-lovastatin combination.
     Expert Opin Investig Drugs, 17(2): 185-95. [Abstract] [Full-text]
104. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806.
     J Clin Oncol, 26(4): 644-9. [Abstract] [Full-text]
105. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
     J Clin Oncol, 26(4): 633-8. [Abstract] [Full-text]
106. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
     J Clin Oncol, 26(4): 592-8. [Abstract] [Full-text]
107. Peribulbar poloxamer for ocular drug delivery.
     Acta Ophthalmol Scand, 86(1): 91-6. [Abstract] [Full-text]
108. Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: primary evidence based on methylation analysis of oestrogen receptor-alpha.
     BJU Int, 101(4): 485-91. [Abstract] [Full-text]
109. Optimized bone regeneration based on sustained release from three-dimensional fibrous PLGA/HAp composite scaffolds loaded with BMP-2.
     Biotechnol Bioeng, 99(4): 996-1006. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.